Parathyroidectomy — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Parathyroidectomy is the surgical removal of one or more of the four parathyroid glands — small (4–8 mm) endocrine glands located on the posterior surface of the thyroid gland in the neck — to treat primary hyperparathyroidism. The parathyroid glands regulate blood calcium levels by secreting parathyroid hormone (PTH), which mobilises calcium from bone, increases intestinal calcium absorption, and reduces calcium excretion by the kidneys. When one or more parathyroid glands becomes overactive (hyperplastic or adenomatous), it produces excessive PTH, causing persistently elevated serum calcium (hypercalcaemia) and its associated complications.

The most common cause of primary hyperparathyroidism is a single benign parathyroid adenoma (85% of cases), followed by multiglandular hyperplasia involving all four glands (10–15%), double adenoma (2–3%), and the rare parathyroid carcinoma (under 1%). The disease is the third most common endocrine disorder after diabetes and thyroid disease, predominantly affecting postmenopausal women.

Modern parathyroidectomy is almost exclusively performed using the minimally invasive technique — a small targeted neck incision guided by pre-operative parathyroid localisation imaging. This approach avoids the full bilateral four-gland neck exploration that was standard before the availability of sensitive sestamibi nuclear medicine scans and neck ultrasound. Minimally invasive parathyroidectomy (MIP) achieves the same cure rate as traditional bilateral exploration with a smaller incision, shorter anaesthesia time, and day-case eligibility for most patients.

Parathyroidectomy is the only definitive treatment for primary hyperparathyroidism and is recommended for all symptomatic patients and for asymptomatic patients meeting established surgical criteria.

Symptomatic primary hyperparathyroidism: Surgery is clearly indicated when patients have symptoms attributable to hypercalcaemia: nephrolithiasis (kidney stones — calcium oxalate or calcium phosphate stones, occurring in 15–20% of patients), overt bone disease (osteitis fibrosa cystica, pathological fractures, reduced bone mineral density T-score below -2.5 at any site), neurocognitive symptoms (fatigue, cognitive impairment, depression), gastrointestinal symptoms (peptic ulcer disease, pancreatitis), and cardiovascular effects (hypertension, shortened QTc interval).

Asymptomatic primary hyperparathyroidism — surgical criteria (Fourth International Workshop, 2022): Surgery is recommended for asymptomatic patients meeting any of the following: - Serum calcium above 0.25 mmol/L (1 mg/dL) above the upper limit of normal (consistent threshold) - eGFR below 60 mL/min/1.73m² (renal impairment) - Bone mineral density T-score below -2.5 at lumbar spine, hip, or distal third of radius on DXA scanning - Vertebral fracture on imaging (radiograph, CT, or vertebral fracture assessment on DXA) - 24-hour urine calcium above 400 mg/day with elevated stone risk on biochemical stone risk assessment - Age under 50 years (young patients have time to develop complications and long-term bone loss)

Contraindications: Severe cardiorespiratory comorbidity precluding general anaesthesia is the primary absolute contraindication. Patients with multiple endocrine neoplasia (MEN1 or MEN2A) require specialised four-gland exploration rather than focused minimally invasive parathyroidectomy due to multiglandular disease.

Modern parathyroidectomy is guided by high-quality pre-operative localisation imaging and validated intraoperatively by rapid PTH measurement.

Pre-operative localisation: Sestamibi (Tc-99m) parathyroid scintigraphy achieves 80–90% sensitivity for identifying a single adenoma. Combined with neck ultrasound (which has 70–80% sensitivity), concordant localisation allows targeted minimally invasive surgery in 75–85% of patients. SPECT/CT fusion provides 3D anatomical localisation and detects ectopic parathyroid adenomas in the mediastinum, thymus, or retro-oesophageal positions. Four-dimensional CT (4D-CT) is used when sestamibi and ultrasound are discordant or negative.

Minimally invasive parathyroidectomy (MIP): Under general anaesthesia, a 2–3 cm transverse incision is made in the neck in a skin crease. Using the imaging localisation as a guide, the identified adenoma is dissected and removed through the small incision with minimal disruption to surrounding structures.

Intraoperative PTH monitoring (Miami criteria): Rapid PTH assay is performed before and 10 minutes after adenoma removal. A drop of greater than 50% from the highest pre-excision PTH level into the normal range constitutes a positive Miami criterion — confirming that all hyperfunctioning parathyroid tissue has been removed. This allows the surgeon to close with confidence without performing a full bilateral four-gland exploration.

Bilateral four-gland exploration: When localisation imaging is negative, discordant, or in the setting of multiglandular disease (MEN syndromes, familial hyperparathyroidism), a traditional bilateral exploration through a slightly larger transverse incision identifies all four parathyroid glands. Subtotal parathyroidectomy (removing 3.5 glands, leaving a vascularised remnant) or total parathyroidectomy with forearm reimplantation is performed for four-gland hyperplasia.

Closure: The wound is closed in layers with absorbable sutures. Drains are generally not required for minimally invasive cases. Most patients are discharged the same day or after one night of observation with calcium monitoring.

Parathyroidectomy achieves high cure rates with durable long-term remission of hypercalcaemia and its associated metabolic complications.

Cure rates: Minimally invasive parathyroidectomy guided by intraoperative PTH monitoring achieves biochemical cure (normalisation of serum calcium and PTH) in 97–99% of cases of single adenoma. Bilateral exploration for multiglandular disease achieves cure in 90–95% depending on completeness of abnormal gland identification.

Recurrence: Disease recurrence after successful parathyroidectomy occurs in under 5% at 10 years for sporadic adenoma. Recurrence rates are higher in MEN1-associated hyperparathyroidism (50% at 12 years) due to the propensity for all four glands to develop disease.

Bone health: Parathyroidectomy improves bone mineral density (BMD) in hypercalcaemia-damaged bone. Lumbar spine BMD typically improves by 5–10% within 1 year and continues to improve for 3–5 years post-operatively, reducing fracture risk. This improvement is not seen with conservative management or medication alone.

Kidney stone prevention: Successful parathyroidectomy reduces the recurrence rate of calcium kidney stones by 60–90%. Patients with previous nephrolithiasis should also maintain adequate fluid intake and may need thiazide diuretics or dietary calcium modifications.

Neurocognitive and quality-of-life improvement: The majority of patients report significant improvements in fatigue, cognitive function, and mood within 3–6 months of surgery, though restoration of pre-disease cognition is not universal.

Parathyroidectomy at high-volume endocrine surgery centres carries a low complication rate, and the risks are substantially reduced by surgeon experience and appropriate pre-operative localisation.

Recurrent laryngeal nerve injury: The recurrent laryngeal nerve (RLN) runs in the tracheo-oesophageal groove immediately behind the thyroid and is at risk during all neck endocrine surgery. Temporary hoarseness from nerve traction or oedema occurs in 2–4% of parathyroidectomy patients and resolves within 3–6 months. Permanent RLN damage causing unilateral vocal cord palsy (hoarse or weak voice) occurs in under 1% at experienced centres. Intraoperative nerve monitoring (IONM) with electromyographic endotracheal tube monitoring is used routinely to identify the nerve and guide dissection.

Post-operative hypocalcaemia: Transient hypocalcaemia occurs in 5–15% of patients after parathyroidectomy. When the adenoma is removed, the remaining parathyroid glands — which have been suppressed for months to years by the elevated calcium from the adenoma — may take days to weeks to resume normal PTH secretion. During this period, serum calcium may fall, causing symptoms of hypocalcaemia: perioral tingling, fingertip paraesthesia, carpopedal spasm, and rarely tetany. This is treated with oral calcium carbonate (1–2 g three to four times daily) and vitamin D supplements. Patients are discharged with calcium supplementation and instructed to seek urgent review if symptoms worsen.

Hungry bone syndrome: Following parathyroidectomy for severe hypercalcaemia with significant bone disease, the skeleton may rapidly absorb calcium once PTH levels fall, causing profound hypocalcaemia — hungry bone syndrome. This is managed with aggressive IV calcium infusion in the peri-operative period and high-dose oral calcium and calcitriol post-operatively.

Haematoma: Neck haematoma causing airway compression is a rare but emergency complication (under 1%) requiring immediate wound opening at the bedside or in theatre.

Persistent or recurrent disease: Persistent hyperparathyroidism (failed cure) occurs in 1–3% of cases, usually due to an ectopic or supernumerary gland not identified on pre-operative imaging. Requires repeat localisation workup including 4D-CT, selective venous sampling, and re-exploration at a specialist centre.

Recovery from parathyroidectomy is typically rapid, and most patients are discharged within 24 hours of surgery.

Immediate post-operative monitoring: Serum calcium is checked 4–6 hours after surgery and before discharge, or the morning after an overnight stay. Any symptoms of hypocalcaemia (tingling, muscle cramps) prompt immediate calcium measurement. Patients are discharged with a supply of oral calcium carbonate 500 mg tablets and instructions to take them three to four times daily if symptomatic or if calcium levels are borderline low.

First week: Mild neck discomfort and a small visible swelling at the incision site are normal. Ice packs and paracetamol manage pain. The wound is kept dry for 48 hours; showering is permitted after that. Sutures dissolve in 4–6 weeks. Patients are advised to avoid strenuous physical activity, heavy lifting, and swimming for 1–2 weeks. Driving is permitted once pain-free and cervical rotation is full — usually within 3–5 days.

Follow-up blood tests: Serum calcium and PTH are checked at 2 weeks post-operatively to confirm cure. Normal calcium with PTH in the reference range confirms biochemical cure. PTH may remain suppressed below normal for several weeks as the remaining glands recover from chronic suppression — this is normal.

Long-term calcium and bone health: Patients with significant pre-operative bone disease are recommended bone-protective therapy — calcium and vitamin D supplementation and in some cases bisphosphonates — under the guidance of an endocrinologist. Annual DXA bone density scans monitor the expected improvement in bone mineral density over 3–5 years post-operatively.

Ongoing surveillance: Annual biochemistry (serum calcium, PTH, creatinine) for 5 years confirms sustained remission and identifies the rare late recurrence. Patients with MEN syndromes require lifelong surveillance with the highest recurrence risk.